Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2018 2
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen NS, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig J; CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. van Gelder M, et al. Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):667-675.e2. doi: 10.1016/j.clml.2017.06.007. Epub 2017 Jun 17. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28694085
BACKGROUND: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase- and BCL2-inhibitors (KI, BCL2i). ...Taking into account the amount of uncertainty for predicting survival after …
BACKGROUND: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free …
Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, Milpied N, Angelucci E, Yakoub-Agha I, Michallet M, Michel G, Aljurf M, Kenzey C, Rocha V, Dalle JH, Bader P, Ruggeri A, Gluckman E; Eurocord, Cellular Therapy & Immunobiology Working Party, and Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. Hayashi H, et al. Biol Blood Marrow Transplant. 2019 Dec;25(12):2438-2446. doi: 10.1016/j.bbmt.2019.07.031. Epub 2019 Aug 5. Biol Blood Marrow Transplant. 2019. PMID: 31394275 Free article. Clinical Trial.

CIF of acute graft-versus-host disease (GVHD) grades II to IV at day 100 was 28%. Three-year CIF of chronic GVHD was 25%. In adjusted analysis, better disease status at UCBT (hazard ratio [HR], 2.74; P < .001) and more recent UCBT (HR, 1.43; P = .01) were associated wit

…
CIF of acute graft-versus-host disease (GVHD) grades II to IV at day 100 was 28%. Three-year CIF of chronic GVHD was 25%. In adjusted …
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.
Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK. Craddock C, et al. J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5. J Intern Med. 2018. PMID: 29214689 Free article.
Later relapse was associated with adverse cytogenetics, mutated NPM1, absence of chronic graft-versus-host disease (GVHD) and the use of in vivo T-cell depletion. ...
Later relapse was associated with adverse cytogenetics, mutated NPM1, absence of chronic graft-versus-host disease (GVHD) and the use …
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.
Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT. Gratwohl A, et al. Ann Hematol. 2016 May;95(6):967-72. doi: 10.1007/s00277-016-2638-6. Epub 2016 Mar 19. Ann Hematol. 2016. PMID: 26994010 Free article. Clinical Trial.
In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). B …
In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of spleni …
Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, Passweg J, Blaise D, Gedde-Dahl T, Poiani M, Fegueux N, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Lorentino F, et al. Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3. Am J Hematol. 2018. PMID: 30058714 Free article.
The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable Cox model, Haplo HSCT recipients experienced comparable OS and LFS to 10/10 and 9/10 UD. ...
The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable …
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, Blaise D, Cornelissen JJ, Meijer E, Diez-Martin JL, Koc Y, Rovira M, Castagna L, Savani B, Ruggeri A, Nagler A, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Sanz J, et al. J Hematol Oncol. 2020 May 6;13(1):46. doi: 10.1186/s13045-020-00882-6. J Hematol Oncol. 2020. PMID: 32375860 Free PMC article.
Interestingly, the use of peripheral blood was associated with an increased risk of acute (HR 1.9; 95% CI 1.4-2.6) and chronic GVHD (HR 1.7; 95% CI 1.2-2.4) but a lower risk of relapse (HR 0.7; 95% CI 0.5-0.9). ...
Interestingly, the use of peripheral blood was associated with an increased risk of acute (HR 1.9; 95% CI 1.4-2.6) and chronic GVHD ( …
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Radujkovic A, et al. Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19. Biol Blood Marrow Transplant. 2015. PMID: 25797175 Free article.
Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT). ...The probability of survival in remission without secondary GVHD was highest (>50% at 5 years) when DLI were g …
Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell tr …
A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.
Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, Huang H, Beelen D, Gorin NC, Craddock C, Gulbas Z, Bacigalupo A, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Piemontese S, et al. J Hematol Oncol. 2017 Jan 19;10(1):24. doi: 10.1186/s13045-017-0394-2. J Hematol Oncol. 2017. PMID: 28103944 Free PMC article.
The type of donor was not significantly associated with neither acute nor chronic graft-versus-host disease. CONCLUSIONS: Patients with acute leukemia in remission have better outcomes if transplanted from a MUD 10/10. ...
The type of donor was not significantly associated with neither acute nor chronic graft-versus-host disease. CONCLUSIONS: Patients wi …